Learn More
OBJECTIVES This phase I, dose-escalation study was conducted to determine the recommended dose of intermittent oral capecitabine in combination with a fixed dose of i.v. oxaliplatin. Secondary objectives included evaluation of the safety profile and antitumor activity. PATIENTS AND METHODS Twenty-three patients with advanced or metastatic solid tumors(More)
  • 1